$BIOCQ
Biocept Inc

2022 Q1 Form 10-Q Financial Statement

#000156459022020962 Filed on May 23, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4 2021 Q1
Revenue $19.90M $13.98M $17.80M
YoY Change 11.8% -24.49% 1127.59%
Cost Of Revenue $10.34M $10.03M $9.010M
YoY Change 14.71% 0.21% 205.42%
Gross Profit $9.610M $3.945M $8.750M
YoY Change 9.83% -53.59% -683.33%
Gross Profit Margin 48.29% 28.23% 49.16%
Selling, General & Admin $10.47M $5.244M $5.043M
YoY Change 107.54% -1.07% 49.66%
% of Gross Profit 108.91% 132.92% 57.63%
Research & Development $1.851M $1.477M $1.040M
YoY Change 77.98% 20.06% -20.61%
% of Gross Profit 19.26% 37.44% 11.89%
Depreciation & Amortization $405.0K $448.2K $370.0K
YoY Change 9.46% 79.26% 54.17%
% of Gross Profit 4.21% 11.36% 4.23%
Operating Expenses $12.32M $6.720M $5.043M
YoY Change 144.25% 2.91% 49.66%
Operating Profit -$2.707M -$2.776M $2.665M
YoY Change -201.59% -240.89% -143.1%
Interest Expense -$61.00K -$70.57K $65.00K
YoY Change -193.85% 17.62% -208.33%
% of Operating Profit 2.44%
Other Income/Expense, Net -$61.00K $0.00 $0.00
YoY Change -100.0%
Pretax Income -$2.768M -$2.846M $2.600M
YoY Change -206.46% -249.8% -131.18%
Income Tax $0.00 $125.0K $0.00
% Of Pretax Income 0.0%
Net Earnings -$2.800M -$2.971M $2.599M
YoY Change -207.73% -256.37% -131.16%
Net Earnings / Revenue -14.07% -21.26% 14.6%
Basic Earnings Per Share -$0.13
Diluted Earnings Per Share -$164.3K -$176.5K $190.2K
COMMON SHARES
Basic Shares Outstanding 16.85M
Diluted Shares Outstanding 16.85M

Balance Sheet

Concept 2022 Q1 2021 Q4 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $27.57M $28.86M $14.20M
YoY Change 94.13% 100.86% -33.92%
Cash & Equivalents $27.57M $28.86M $14.20M
Short-Term Investments
Other Short-Term Assets $446.0K $391.0K $700.0K
YoY Change -36.29% -81.81% 62.79%
Inventory $3.221M $2.651M $3.260M
Prepaid Expenses
Receivables $16.35M $13.79M $17.14M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $47.58M $45.69M $35.30M
YoY Change 34.8% 40.18% 34.42%
LONG-TERM ASSETS
Property, Plant & Equipment $2.380M $2.401M $14.56M
YoY Change -83.65% 3.58% 310.14%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $471.0K $456.0K $440.0K
YoY Change 7.05% 7.04%
Total Long-Term Assets $14.36M $14.73M $15.00M
YoY Change -4.27% -0.9% 322.54%
TOTAL ASSETS
Total Short-Term Assets $47.58M $45.69M $35.30M
Total Long-Term Assets $14.36M $14.73M $15.00M
Total Assets $61.94M $60.42M $50.30M
YoY Change 23.15% 27.32% 68.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.076M $7.246M $7.300M
YoY Change 10.63% -13.39% 202.9%
Accrued Expenses $4.550M $3.018M $3.440M
YoY Change 32.27% -4.67% 20.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $1.021M $1.083M $1.180M
YoY Change -13.47% 12.81% 63.89%
Total Short-Term Liabilities $14.10M $11.77M $11.91M
YoY Change 18.35% -5.79% 97.51%
LONG-TERM LIABILITIES
Long-Term Debt $1.221M $1.428M $1.820M
YoY Change -32.91% -2.19% 73.33%
Other Long-Term Liabilities $9.598M $9.736M $9.800M
YoY Change -2.06% -0.75%
Total Long-Term Liabilities $10.82M $11.16M $11.62M
YoY Change -6.89% -0.94% 1006.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.10M $11.77M $11.91M
Total Long-Term Liabilities $10.82M $11.16M $11.62M
Total Liabilities $24.92M $22.94M $23.53M
YoY Change 5.9% -3.47% 232.31%
SHAREHOLDERS EQUITY
Retained Earnings -$269.1M -$266.4M -$260.9M
YoY Change 3.13% 1.09%
Common Stock $303.8M $287.7M
YoY Change 5.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $37.03M $37.48M $26.77M
YoY Change
Total Liabilities & Shareholders Equity $61.94M $60.42M $50.30M
YoY Change 23.15% 27.32% 68.73%

Cashflow Statement

Concept 2022 Q1 2021 Q4 2021 Q1
OPERATING ACTIVITIES
Net Income -$2.800M -$2.971M $2.599M
YoY Change -207.73% -256.37% -131.16%
Depreciation, Depletion And Amortization $405.0K $448.2K $370.0K
YoY Change 9.46% 79.26% 54.17%
Cash From Operating Activities -$900.0K $1.563M $844.0K
YoY Change -206.64% -240.81% -115.99%
INVESTING ACTIVITIES
Capital Expenditures -$98.00K -$590.1K $712.2K
YoY Change -113.76% -27.15% 3748.28%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$98.00K -$590.1K -$712.0K
YoY Change -86.24% -27.15% 3747.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -268.0K 192.7K -302.0K
YoY Change -11.26% -133.22% -101.73%
NET CHANGE
Cash From Operating Activities -900.0K 1.563M 844.0K
Cash From Investing Activities -98.00K -590.1K -712.0K
Cash From Financing Activities -268.0K 192.7K -302.0K
Net Change In Cash -1.298M 1.166M -170.0K
YoY Change 663.53% -146.62% -101.39%
FREE CASH FLOW
Cash From Operating Activities -$900.0K $1.563M $844.0K
Capital Expenditures -$98.00K -$590.1K $712.2K
Free Cash Flow -$802.0K $2.153M $131.8K
YoY Change -708.51% -817.7% -102.49%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y21D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y9M10D
CY2021Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1923000
CY2021Q1 us-gaap Interest Expense
InterestExpense
65000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
37029000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
23692000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
460000
CY2021Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
19000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
2599000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
2599000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-2768000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
366000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
405000
CY2021Q1 bioc Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
362000
CY2022Q1 bioc Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
414000
CY2021Q1 bioc Increase Decrease In Inventory Reserve
IncreaseDecreaseInInventoryReserve
9000
CY2022Q1 bioc Increase Decrease In Inventory Reserve
IncreaseDecreaseInInventoryReserve
-78000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
460000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2317000
CY2021Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-4000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1320000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2998000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2564000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
648000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1454000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
49000
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
13000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
16000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-333000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
375000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
272000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1524000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
844000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-932000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-712000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-98000
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
18000
CY2021Q1 bioc Proceeds From Exercise Of Overallotment Warrants
ProceedsFromExerciseOfOverallotmentWarrants
1000
CY2021Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
321000
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
268000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-302000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-268000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-170000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1298000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14368000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28864000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14198000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27566000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
65000
CY2021Q1 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
894000
CY2022Q1 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
0
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
319000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
60000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17756000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19945000
CY2021Q1 bioc Reserve Related To Aged Account Receivable
ReserveRelatedToAgedAccountReceivable
600000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17756000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19945000
CY2021Q1 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
4300000
CY2022Q1 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
2700000
CY2022Q1 us-gaap Cash
Cash
27600000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-269100000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-2800000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2800000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
800000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-900000
CY2022Q1 bioc Aggregate Net Interest Bearing Indebtedness
AggregateNetInterestBearingIndebtedness
2200000
CY2022Q1 bioc Aggregate Net Interest Bearing Indebtedness Due Within One Year
AggregateNetInterestBearingIndebtednessDueWithinOneYear
1000000.0
CY2022Q1 bioc Other Non Interest Bearing Current Liabilities
OtherNonInterestBearingCurrentLiabilities
13100000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19900000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17800000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2800000
CY2020Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1900000
CY2021 bioc Warrant Inducement Expense
WarrantInducementExpense
2100000
CY2020Q1 bioc Estimated Grant Date Fair Value Of Warrants
EstimatedGrantDateFairValueOfWarrants
2.80
CY2020Q1 bioc Unregistered Warrants Issued Grant Date Fair Value
UnregisteredWarrantsIssuedGrantDateFairValue
1900000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2401000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2380000
CY2021Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
961000
CY2021Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
178000
CY2021Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
600000
CY2022Q1 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
1813000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
554000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
434000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3018000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4550000
CY2021Q1 bioc Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
21330
CY2021Q1 bioc Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
1100000
CY2021Q1 bioc Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
2026-03
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9026000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8892000
CY2021Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
2842000
CY2022Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
2617000
CY2021Q4 bioc Operating And Finance Lease Right Of Use Assets
OperatingAndFinanceLeaseRightOfUseAssets
11868000
CY2022Q1 bioc Operating And Finance Lease Right Of Use Assets
OperatingAndFinanceLeaseRightOfUseAssets
11509000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
426000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
449000
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1083000
CY2022Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1021000
CY2021Q4 bioc Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
1509000
CY2022Q1 bioc Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
1470000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9736000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9598000
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1428000
CY2022Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1221000
CY2022Q1 bioc Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
10819000
CY2022Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
225000
CY2022Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
61000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
415000
CY2022Q1 bioc Operating And Finance Lease Cost
OperatingAndFinanceLeaseCost
701000
CY2022Q1 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
819000
CY2022Q1 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Remainder Of Fiscal Year
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsRemainderOfFiscalYear
92000
CY2022Q1 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
963000
CY2022Q1 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Due Next Twelve Months
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueNextTwelveMonths
106000
CY2022Q1 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
534000
CY2022Q1 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Due In Two Years
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueInTwoYears
29000
CY2022Q1 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
185000
CY2022Q1 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Due In Three Years
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueInThreeYears
3000
CY2022Q1 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
15000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1762000
CY2022Q1 bioc Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
8518000
CY2022Q1 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
2516000
CY2022Q1 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
274000
CY2022Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
2242000
CY2022Q1 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
61000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
396000
CY2021Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
321000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1155570
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.35
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
365250
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.44
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
268000
CY2022Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y6M
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y3M
CY2022Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.190
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.120
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2413194
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.04
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3203514
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.50
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3162485
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.52
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y11M19D
CY2021Q4 bioc Common Stock Warrants Outstanding Intrinsic Value
CommonStockWarrantsOutstandingIntrinsicValue
16000
CY2022Q1 bioc Common Stock Warrants Outstanding Intrinsic Value
CommonStockWarrantsOutstandingIntrinsicValue
0
CY2021Q1 bioc Number Of Warrants Included In Calculation Of Dilutive Weighted Average Shares
NumberOfWarrantsIncludedInCalculationOfDilutiveWeightedAverageShares
256461
CY2021Q1 bioc Number Of Options Included In Calculation Of Dilutive Weighted Average Shares
NumberOfOptionsIncludedInCalculationOfDilutiveWeightedAverageShares
102708
CY2021Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
267709
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2251834
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4106947
CY2022Q1 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
1600000

Files In Submission

Name View Source Status
R24.htm Edgar Link pending
R25.htm Edgar Link pending
0001564590-22-020962-index-headers.html Edgar Link pending
0001564590-22-020962-index.html Edgar Link pending
0001564590-22-020962.txt Edgar Link pending
0001564590-22-020962-xbrl.zip Edgar Link pending
bioc-10q_20220331.htm Edgar Link pending
bioc-10q_20220331_htm.xml Edgar Link completed
bioc-20220331.xsd Edgar Link pending
bioc-20220331_cal.xml Edgar Link unprocessable
bioc-20220331_def.xml Edgar Link unprocessable
bioc-20220331_lab.xml Edgar Link unprocessable
bioc-20220331_pre.xml Edgar Link unprocessable
bioc-ex101_201.htm Edgar Link pending
bioc-ex311_8.htm Edgar Link pending
bioc-ex312_9.htm Edgar Link pending
bioc-ex321_6.htm Edgar Link pending
bioc-ex322_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending